ADC Technology: A Premier Institution of Antibody-Drug Conjugates Development

New York, United States—April 20, 2022—ADC Technology, one of the major departments at BOC Sciences, released today a wide range of one-stop services related to antibody-drug conjugates (ADC) development such as antibody selection/modification, ADC payload and linker development, ADC conjugation, and ADC characterization and preclinical evaluation. ADC Technology possesses GMP-grade and ISO-certified contract manufacturing facilities and exploits a custom development platform of antibody-drug conjugates to help partners win the race of ADC research.

Antibody-drug conjugates (ADC) are coupled by monoclonal antibodies (mAb) and small-molecule drugs through linkers. The specificity of mAb on tumor cells enables small molecule drugs to target tumor tissue, effectively reducing the high toxicity of traditional small molecule drugs and improving the overall treatment efficiency. The advent of ADCs offers a promising treatment for many types of cancer. As more ADC drugs enter clinical trials, the industry is gradually moving away from traditional technologies to new, powerful technologies to provide novel ADCs. As a pioneering institution engaged in ADC research for many years, ADC Technology Department offers a complete range of flexible ADC manufacturing services, from process development and analytical support to GMP production.

To be more specific, ADC Technology provides biopharmaceutical contract research and development, process development, cGMP manufacturing, as well as comprehensive QA and QC solutions for scientific research, preclinical, clinical, and commercial supply. Based on its cutting-edge custom ADC development platform and extensive experience with organic synthetic chemistry and R&D in GMP environments, ADC Technology supports GMP-scale route design as well as optimization for payloads and payload linkers, including the use of HPAPI products. Take ADCs conjugation, for example, the experts apply random conjugation or site-specific conjugation methods according to client requirements. In addition, ADC Technology uses advanced filtration equipment, such as ultrafiltration and tangential flow filtration (TFF) systems to remove therapeutic impurities and achieve optimum purification.

“We are equipped with cGMP grade laboratory facilities and system, and our personnel is well versed in antibody modification and conjugation technologies. We have a dedicated custom development platform that it’s very convenient for customers to customize different ADC products and services.” Said the Marketing Director at ADC Technology Department, “we can guarantee researchers high-quality products from gram to kilogram scales and professional technical support to help them win the race of ADC research.”

About ADC Technology

ADC Technology, one of major the departments at BOC Sciences, provides the most complete set of solutions in antibody-drug conjugate (ADC) drug development services in the pharmaceutical industry. Working with companies and academic groups all over the world, including most of the top biopharmaceutical companies, ADC Technology supports the development and manufacture of antibody-drug conjugates.